| Q46843900 | Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients |
| Q38749357 | Adulterated and Counterfeit Male Enhancement Nutraceuticals and Dietary Supplements Pose a Real Threat to the Management of Erectile Dysfunction: A Global Perspective. |
| Q26795512 | Current use of phosphodiesterase inhibitors in urology |
| Q36689825 | Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? |
| Q37686844 | Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives. |
| Q35827790 | Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. |
| Q24246544 | Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus |
| Q36993658 | Phosphodiesterase type 5 inhibitors: state of the therapeutic class |
| Q50698078 | Sexual counselling for individuals with cardiovascular disease and their partners: a consensus document from the American Heart Association and the ESC Council on Cardiovascular Nursing and Allied Professions (CCNAP). |
| Q37472745 | Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents |
| Q41978073 | Tadalafil in the treatment of erectile dysfunction |
| Q37321940 | The use of phosphodiesterase 5 inhibitors with concomitant medications. |
| Q34244951 | cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action |
Search more.